

Alzheimer's
Research UK
Defeating Dementia

OUR YEAR

ANNUAL REVIEW 2015



What we do



Alzheimer's Research UK is the UK's leading dementia research charity. Our vision is a world free from dementia.

Our mission is clear, we conduct world-class research to prevent, treat and cure dementia. We help people to understand dementia and the progress we are making. We forge partnerships with government and other key organisations to make dementia research a national priority.

This year we developed and launched our Defeat Dementia campaign, which aims to raise £100 million for dementia research over the next five years. This campaign will help find new scientific breakthroughs and put these discoveries to work to benefit people with dementia.

We have had our strongest financial year to date with total incoming resources reaching £14,232,552 – a 29% increase from 2013. This has allowed us to put more than ever into charitable activity. We are very proud of our achievements over the last year that will help make defeating dementia a reality.

Contents



INTRODUCTION FROM VICKI GRAHAM 3

WHY WE NEED TO DEFEAT DEMENTIA 4

OUR WORK IN PREVENTING DEMENTIA 7

DETECTING AND DIAGNOSING 8

TREATING DEMENTIA 10

DELIVERING DRUGS TO PEOPLE 12

YOUR FUNDRAISING 14

OUR YEAR IN NUMBERS 16

OUR FINANCES 17

THANK YOU 18

Alzheimer's Research UK Champion Vicki Graham's husband Jamie has early-onset Alzheimer's. She explains why our Defeat Dementia campaign is vital – and what drives her and her family to share their story.

"Research gives us hope – it's the only answer."

Jamie used to make friends immediately with everybody, wherever we went. He loved playing the guitar. He was full of fun, had a dry wit and loved playing with words. We lived in the US for many years when Jamie worked as an IT executive. He thought nothing of giving a speech to hundreds of people. And he was exceptionally proud of his children.

Now Jamie can't remember how to get in the car. He puts one foot in and can't work out how to sit. He hardly speaks and struggles to feed or dress himself.

Jamie was diagnosed with early-onset Alzheimer's in 2007, aged just 59.

In the early years, I went through a grieving process, crying all the time. Then I got a sort of rage that this disease has totally changed the big, strong man I've known since he was 14.

That's why I'm happy to do anything to make people aware of the horrors of dementia, and let them know that masses more money is needed for research. In this annual review, my daughter Nina, my daughter-in-law Roz and I tell our family's story. We want to show how much the Defeat Dementia campaign needs your support.


Research is the only answer. But while dementia costs the UK economy more than cancer and heart disease combined, it only gets a fraction of the research funding.

We need your help to rectify this, and defeat the disease that's taken so much from my husband and family. Please join us on our journey to Defeat Dementia.

Thanks for your support.
Vicki Graham



IMAGE: Nerve fibres in a healthy adult human brain.
Zeynep M. Saygin, McGovern Institute, Wellcome Images.



Why we need to Defeat Dementia

Ian Wilson, Director of Fundraising, and Hilary Evans, Director of External Affairs, reflect on why our Defeat Dementia campaign, launched at the Global Action on Dementia Summit in June 2014, is urgently needed. With your support, it could lead to groundbreaking new treatments.

Ian discusses our ambitious fundraising target:



Dementia is not an inevitable, natural or a normal part of ageing. It's an awful condition

where over time symptoms grow worse and in later stages many people require 24-hour care, by which time they may be unable to communicate and will be experiencing acute psychiatric symptoms. The story you will hear from the Graham family is why it's so important to take a big step forward for research into dementia. To do this, we've set an ambitious target – to raise £100 million over the next five years as part of our Defeat Dementia campaign. We need to generate the type of investment there was for HIV and Aids in the 1980s and 1990s, and that there has been in cancer.

Thanks to you, **in 2014 we've been able to raise over £14.2 million** which has allowed us to invest over £9.7 million in charitable activity, including committing £7.6 million for new research – our highest figure to date. In addition we have been able to designate a further £1.5 million towards the Drug Discovery Institute initiative which will commence in 2015. We're investing in truly pioneering research and we have the ideas, links to pharmaceutical companies and government, and global collaborations, to find treatments for dementia. Our work is catalysing a movement that is getting closer

to finding a cure for dementia. With increased investment our aim is to have **800 more scientists working in this area**, a network of pioneering **Drug Discovery Institutes** and new therapies to cure or treat dementia. We've got to act now. If we don't, more people like Jamie, Vicki, Nina and Roz will have to deal with this life shattering disease.

I believe Defeat Dementia will drive forward a drug or treatment to benefit people affected by the condition. The last year has given us a strong platform upon which to build and we now need to capitalise on this.

Hilary explains the progress we have made over the past year:



The need to defeat dementia has never been more urgent. We're living longer which

means more people will have the condition in the future – one in three people over 65 in the UK will die with dementia. And by 2050, around 135 million people worldwide will have dementia.

It is a global problem, but until you hear the stories of people affected by dementia, like the Grahams, it doesn't necessarily hit home. Dementia is a devastating condition that destroys lives. There's also an economic impact. The costs of looking after people with dementia are huge, with the vast majority of the cost shouldered by families.

Last year, we played a key role in **the G8 Summit** in London in December 2013. This saw the G8 countries all agreeing to work together with an aim of achieving a cure or disease-modifying treatment for dementia by 2025. It's fantastic that G8 leaders committed to this goal. Our research initiatives show how Alzheimer's Research UK will play a major role in making it happen.

We're funding a **Global Clinical Trials Fund** which will deliver innovative drugs trials, turning promising findings into treatments for people as quickly as possible. **Our Dementia Consortium** has already created partnerships between researchers and pharmaceutical companies which are helping develop crucial leads for new drugs. We're the leading dementia research charity in the UK, and are increasingly influential internationally because we can form alliances with public and private funders the world over. That means we are uniquely placed to be able to move quickly and flexibly in our research – with the aim to get benefits to patients as soon as possible.

We've made great progress over the last year with increased media attention for dementia and the **Prime Minister's Dementia Challenge** and his public support for our campaign has been helpful in raising awareness of the condition. With our supporters' help, we will make progress towards a cure for generations to come.

Our work in preventing dementia

Research is key to finding out more about how we can reduce our risk of developing dementia, says Dr Simon Ridley, Head of Research at Alzheimer's Research UK.



If we better understand and address the factors that contribute to dementia

risk, we could reduce the number of people who have it by up to a third. Having more solid evidence about how people could reduce their risk of developing the condition by making changes to their lifestyle could make a big difference.

Preventing dementia is a core part of Alzheimer's Research UK's strategy. In May 2014, we were one of 59 UK experts in dementia to sign The Blackfriars Consensus on Promoting Brain Health, calling for further research into dementia prevention, an important step to tackling the condition in a more collaborative way.

As part of our **Defeat Dementia campaign**, our **Prevention Fund** will provide vital backing for research in this under-funded area. We'll map what prevention research is happening and consult an expert panel on what gaps there are and how we can work together to fill them.

This year we have committed to **supporting an exciting long-term study following people born within a few weeks of each other in the 1940s**. Crucially, it removes the major risk factor of age so we can more clearly link the effects of other aspects of people's lives and health to their risk of developing dementia. We need more long-term studies like this to obtain evidence on what we think we know about prevention and to promote what we do know so we can better prevent dementia.

"Someone needs to stop this immensely cruel disease."



Vicki explains how Jamie's Alzheimer's has caused his deterioration, the everyday difficulties of living with the disease, and how it has changed their lives.

In 2010 and 2011, Jamie did two sponsored rows that raised £200,000 for Alzheimer's Research UK. He could still get in a boat with some help from his fellow oarsmen. But, as the training ended, he lost the ability to row by himself. He also forgot how to get on his bike, and as the exercise stopped, his mental awareness seemed to suffer. Last year, he was still able to play tennis, but that's gone now too.

Nowadays, Jamie hardly speaks. For someone who was so funny and articulate, who used to hold court at dinner parties, the loss of words has been most significant.

Jamie likes to wander now. We're fortunate to have a closed-in garden and fields he can wander in safely.

Feeding himself is a struggle. Jamie can cope with a spoon, but not a knife and fork. The plates have to be white; if they're patterned he confuses the pattern with the food. I have to dress and undress him and help him shower.

He is easy-going. I know some people with Alzheimer's can be aggressive, but Jamie's only like that if you try to force him to do something he doesn't want to.

Jamie was very gregarious and popular, and we enjoyed a full social life before his diagnosis. It became very apparent very quickly who our best friends were. You could count them on one hand – the invitations stopped coming. Obviously people are afraid and embarrassed about how to communicate with someone with dementia.

I get help every day from a carer but otherwise it's just the two of us. Jamie doesn't take too kindly to other people doing personal things.

Is life difficult? Yes. But we've been through so much together, and I really can't cope with the thought of someone else looking after him. I'm not going to just hand him over. But as the demands of caring for Jamie grow greater with time, it's supporting research that really gives me hope. Only the scientists can solve this problem. Someone needs to stop this immensely cruel disease.

Detecting and diagnosing dementia

Prof Simon Lovestone is based at the University of Oxford and is working on research that will make it easier to detect early stage Alzheimer's disease.



We do clinical trials too late in the disease process when Alzheimer's is already well advanced. We

need to trial drugs for the disease much earlier – ideally before any symptoms, and certainly before dementia is fully established. We know that the protein amyloid starts to build up, and begins to damage the brain, up to 15 years before symptoms like memory loss develop.

For the last decade, I've worked on Alzheimer's Research UK-funded research to use biomarkers, molecules in the body, to **detect Alzheimer's at a very early stage**. My team and I measured 10 proteins in the blood of people who have early memory and thinking problems. We were able to predict with 87% accuracy who would go on to develop Alzheimer's within a year.

The results of my team's research, which attracted much attention in the press during summer 2014, is promising as it helps us to better understand the early stages of Alzheimer's, and detect the very early processes of disease before dementia. If this becomes a simple test to measure proteins in the blood,

it could help researchers recruit the most appropriate people to clinical trials for new treatments. Participants could receive potential new treatments at a time when they're most likely to benefit from them.

We need to trial our findings using more blood samples, to further improve accuracy and reduce the risk of misdiagnosis. As well as assisting in the design of clinical trials, we hope that measuring biomarkers in the blood feeds into efforts to improve diagnosis tools available to doctors, for use when symptoms emerge. Doctors need the time, training and tools to diagnose dementia as early as possible so people like Jamie and his family can get support.

Recruiting people with very early stage Alzheimer's for clinical trials will support the work of Alzheimer's Research UK's Drug Discovery Institutes. We'll be better able to test whether new drugs can slow progress of the disease.

Alzheimer's Research UK has made an important contribution to research into early detection of Alzheimer's and, in the last 12 months, our understanding of the disease has really begun to accelerate.

Jamie and Vicki's daughter-in-law, Roz, a psychiatrist for older people, talks about Jamie's deterioration – and the day he was diagnosed with Alzheimer's, aged just 59, in 2007.



"It's not the diagnosis you want to hear."

I'd never seen him like that. His company let him go because he wasn't performing and he and Vicki moved home. He started on anti-depressants, and they improved his mood, but it became obvious he had some kind of cognitive difficulty too. For example, his driving became erratic.

Jamie had a brain imaging scan as part of a research project at Imperial College in London, and that confirmed it was Alzheimer's. I was there when the doctor gave Jamie and Vicki the diagnosis. They were both incredibly brave; they are amazing people.

Getting the diagnosis alleviated the frustration we sometimes felt about Jamie struggling with things, and the uncertainty. It helped him get medication and support. But it's not the diagnosis you want to hear. Jamie was lucky to get the scan – that isn't freely available. A simple blood test, like Prof Lovestone's research is ultimately working towards, would be very beneficial – although it needs to come with new treatments too.

Jamie and Vicki are remarkable. All the hopes they had for their retirement have been destroyed, but Vicki still talks about how lucky she is in many respects. She's treated Jamie with such love and respect. But she's lost her life partner, my husband Magnus has lost the dad he knew and loves so much and my children have lost their grandfather. We don't want any other family to go through this.

I think, really, I knew what was going on when I asked Jamie the time one day back in 2006. He couldn't read his watch. At that point, he was still trying to work in a high powered job in IT.

Before that, the signs had been more subtle over about five years; it's often the way

with Alzheimer's – it comes on gradually. Jamie seemed more stressed, which we put down to getting older and still having to travel into London and work long hours.


Then his job moved to New York in 2004. When we visited, Jamie was low and withdrawn.

Treating dementia



It takes about six months to turn skin cells donated by people who have inherited

Dr Rick Livesey leads our Stem Cell Research Centre, which was launched in 2014, and has created stem cell models in the laboratory which could help develop future treatments for Alzheimer's disease.



Brain stem cells made from patient skin cells - Copyright Livesey group, Gurdon Institute, University of Cambridge.

the genetic 'familial' form of Alzheimer's into working nerve cells in the laboratory. Turning them into the bits of the human brain that get affected by dementia takes another three months. This process of creating what has been called '**Alzheimer's in a dish**' allows us to learn how the disease starts and spreads through the brain and to test compounds that could slow or stop it.

Alzheimer's Research UK was the first to support our early work in this field using stem cells donated by people with Down's syndrome, who are at very high risk of developing Alzheimer's. The technique has allowed us to create stem cell models from six people with familial Alzheimer's disease, which we're using to test drugs that pharmaceutical companies are working on.

At the moment we only have two main hypotheses about how to treat Alzheimer's disease, which involve interfering with the production of two proteins – amyloid and tau – which build up in the brain during the disease. Our work will generate more testable hypotheses about the disease, benefiting people like Jamie in the future because this will help develop treatments.


This year, my team of 18 researchers based at the University of Cambridge have joined forces with clinicians and genetics experts at the Institute of Neurology at University College London to form **The Alzheimer's Research UK Stem Cell Research Centre**.

This innovative Centre has been made possible with support from The Alborada Trust and was launched in June 2014 on the day of the first legacy event of the G8 Dementia Summit. Pooling expertise and resources will help us better understand the nuts and bolts of the disease, develop stem cell models from more people and test treatments that are more likely to work.

Stem cell research can transform how we approach dementia science and this new centre means the UK can now lead the field in this important area of research. Treatments come from talented scientists doing thorough research over a number of years and Alzheimer's Research UK is a critical part of that. Without them, we wouldn't have been able to develop the work we've done in our laboratory.

Our understanding of treating dementia will be unrecognisable in 10 years' time if we carry on funding research in this area.

Vicki explains how little treatment is available for Jamie and other people with dementia.



For a disease that is ravaging my husband and 830,000 other people in the UK, there is shockingly little treatment.

Jamie takes the only drugs available to him, which can temporarily improve his symptoms of Alzheimer's. He also takes an anti-depressant. I think the medication keeps him in a happier place – if he had no drugs at all he probably wouldn't be so active.

But there's nothing out there to treat Alzheimer's. Nothing to cure it. That's why research into treatments and the Stem Cell Research Centre are so important.

Medication aside, Jamie's big therapy is music. The night we got together, at a party in 1970, he was playing his guitar and everyone was singing along with him. I loved his music right away. One of the early signs of his Alzheimer's was forgetting words of songs in his repertoire, which was so out of character for him.

Our daughter Nina has put his whole collection on an iPod, from Scottish fiddle music to Elvis. I clip it to the back of his collar because he struggles to hold it. He can't change songs or choose what he wants, I do that, but when the music stops he starts huffing. The rhythm's still there; he'll sing a bit and sort of air guitar and move his foot to the beat. When there's music, he's happy.

"**There's nothing to treat Alzheimer's. Nothing to cure it.**"

Delivering drugs to people

Our Drug Discovery Institutes and Global Clinical Trials Fund will help make new drugs for dementia a reality, says Dr Eric Karran, Director of Research at Alzheimer's Research UK.



The brain is probably the most complex 1.5 kilograms in the known universe. I

started working in neuroscience 36 years ago because I was fascinated by how much we do and don't know about the processes of memory. Our lack of knowledge makes finding good medicines to stop this aggressive disease incredibly difficult.

At the moment, we have four recommended drugs that can alleviate the symptoms of Alzheimer's. Drugs like Aricept help with memory problems and Memantine can support people with moderate to severe Alzheimer's. Neither works well or for very long.

We need drugs to prevent dementia, others to slow – or stop – progress of it in the brain and better medicines for people in the late stages of the condition. The scientific community needs to spend more time understanding

the mechanisms by which brain cells die in diseases like Alzheimer's and others that cause dementia.

We've built our reputation on responsively funding the most innovative ideas from the field to get closer to completing the complicated picture of what leads cells to die. This year is no exception to that, with £7.6m invested in 62 new projects at centres across the UK. Ranging from large collaborative studies to pioneering pilot projects, they allow us to explore every research angle and test new approaches, theories and hypotheses.


Our £30 million investment in our Drug Discovery Institutes builds strategically on our responsive funding, and will provide even more opportunities for scientists to drive drug development for people with dementia. Each Institute will be staffed with up to 30 scientists whose role will be to accelerate the innovation of the academic scientists around them to provide patient

benefits – from 'bench-to-bedside'. By embedding these Institutes in top academic centres, we will bring the best of academic and drug discovery expertise together. **Researchers at the Drug Discovery Institutes and from around the world will also be able to access our £20 million Global Clinical Trials Fund** to test the drugs they produce in clinical trials with the most appropriate people.

Some drugs that target an important and damaging protein called amyloid are showing the potential to slow down Alzheimer's disease – although further testing is needed and is currently underway. So, we could be just a few years away from a drug that slows the progression of dementia. As a charity, Alzheimer's Research UK has the independence, credibility and expertise to accelerate findings in the laboratory into benefits for people like Jamie as soon as possible.

Jamie and Vicki's daughter Nina explains the toll Alzheimer's has taken on her family, and why we all need to take action now

"It's absolutely vital that we get more money for research, and make more treatments available."



Dementia is one of the most terrifying medical conditions facing our generation. I don't think my generation has a sense of how widespread it is. It really needs to be recognised. My parents have been very open about my dad's diagnosis. Now more and more of my friends are coming to me, concerned about their parents.

On full power, my dad was a special person. He was amazing, actually. People just loved him – he was a real presence. Dad was a party man and entertainer. He was extremely affectionate, and involved in our childhoods. He was very positive, and encouraged my brother and I to go after what we wanted in life. He wanted to travel a lot and we benefited hugely from that, living in the US. He worked hard and achieved his dreams.

My family and I live in Dubai, and it's very difficult seeing my dad when we come back. Between visits we tend to see a lot of deterioration. It can be quite shocking. I just miss him. My husband does too; he's in a similar career to my dad and misses being able to talk to him about it. It's been very wearing on us.

It's hard not being able to support my mum day to day. She's been through the whole spectrum of emotions and responses to grief, from anger to asking 'Why has this happened to us?', and being determined to do everything she can to defeat the condition.

It's definitely aged her in the past few years, and stolen a lot of opportunities she deserved in her retirement. They both did. She's living a life she never imagined; I certainly didn't imagine it for her. But at the same time, it's shown her to be incredibly strong and resilient.

Alzheimer's Research UK's Defeat Dementia campaign is amazing. It's absolutely vital that we get more money for research, and make more treatments available. It's got to be done. Research is the only answer to dementia – new treatments being developed at the Drug Discovery Institutes and through the Global Clinical Trials Fund could improve the lives of millions of people like my dad.

Your fundraising

Thanks to the generosity of our supporters, fundraisers, donors and volunteers, in 2014 we've invested £9.7 million in charitable activity, including committing £7.6 million for new research – our highest figure to date. In addition to this we have been able to designate a further £1.5 million towards the Drug Discovery Institute initiative which will commence in 2015.

Record-breaking Marathon runners

Our amazing London Marathon runners raised over £100,000 to fight dementia in 2014. Inspirational fundraiser Susie Hewer smashed her own world record for making the longest crochet chain while running a marathon. Her 2014 chain was 139.42 metres long – a whopping 62 metres longer than the one which landed her the record in 2010. Susie has now run 38 marathons for Alzheimer's Research UK and has pledged to run 13 marathons in just 12 months to further boost funds.

We received the first gift from our largest ever pledge, from the Alborada Trust

The Alborada Trust's pledge of £1,970,704 over five years for the Alzheimer's Research UK Stem Cell Research Centre at the University of Cambridge and UCL is the largest commitment we have so far received from a charitable trust. It is also among the



largest that the Alborada Trust has ever made to any charitable project and supports the biggest grant we have made in our 21-year history to a single institution.

Passing 10,000 regular givers

In July 2014 we passed the significant milestone of 10,000 Direct Debit supporters. This means that during the last year our generous regular givers donated over £840,000 towards groundbreaking research. Regular givers are vital to Alzheimer's Research UK as they provide a dependable source of income, enabling us to better plan our research funding. We are so grateful to everyone who chooses to support us in this way. We hope to increase the number of people who regularly make a donation to Alzheimer's Research UK, with the aim of raising over £1 million from regular givers in the next 12 months.

Biggest ever legacy

This year, we received our biggest legacy to date from Mrs Betty Shadbolt. After providing for family and friends and gifts to registered charities, Mrs Shadbolt gave Alzheimer's Research UK a one seventh share in her residual estate. In doing so, the liability to Inheritance Tax was reduced and to date, Mrs Shadbolt's gift has supported £620,000 of vital dementia research. Gifts in Wills pay for one in three of our research projects and in

the last 12 months, Alzheimer's Research UK raised £4.6 million in legacy income - our highest ever total. We are extremely grateful to those who remember Alzheimer's Research UK in their Will.

Cool £3.1m from Iceland Foods Charitable Foundation

The Iceland Foods Charitable Foundation presented a cheque for £1 million to Alzheimer's Research UK in March, bringing its total fundraising efforts to £3.1 million. This is thanks to a nationwide effort by the frozen food supermarket's staff during our three-year fundraising partnership, which concluded in 2014.

The regionalisation of our community fundraising programme

In 2014 we appointed our first Regional Fundraising Officers based in the North and East of England. Over the coming months, recruitment will be undertaken in the South East and West of England. This change allows Regional Fundraising Officers to engage with supporters in key areas and to maximise their contact time. This special group of Fundraising Officers is responsible for inspiring our army of dedicated fundraisers to raise further funds for Alzheimer's Research UK and for engaging volunteers at collections, events and other opportunities.

As well as having a strong presence in their areas, Regional Fundraising Officers keep in touch with what is happening at our headquarters by making regular visits to head office.

Star line-up for ICAP Charity Day

On 3 December 2013, a line-up of our celebrity supporters, including patron Lindsay Duncan, presenter Fiona Phillips, Dragons' Den star Deborah Meaden, choreographer Arlene Phillips and TV entertainer Russell Grant, attended the ICAP Charity Day to represent Alzheimer's Research UK. For one day, the leading financial services company gives away all its revenues and commissions to charity, and the 2013 day raised an amazing £9.5 million for charity worldwide. ICAP's Charity Day donation to Alzheimer's Research UK will support two pioneering dementia research projects. The first is improving the timeliness and accuracy of dementia diagnosis, and the second is looking at how the condition affects blood vessels in the brain. It also funded the production and distribution of our 'What is Alzheimer's?' leaflet.

The 2013 ICAP Charity Day raised an amazing £9.5 million for charity worldwide.

Our year in numbers



25,000

The number of locations we sent **free information** on dementia to including every GP surgery, library and old-age and dementia care home in the UK. It means we've distributed over 236,000 leaflets giving people affected by dementia the expert advice, information and reassurance they need at a difficult time.



300,000

The number of unique visits to our **website** providing people with up-to-date **information** on the latest dementia research, trustworthy health information, how to make donations and the many different ways to take part in fundraising.



43,462

The number of people who have visited our social media app **FaceDementia** since it launched in April 2014. Our biggest ever digital launch, FaceDementia was designed to provide a tool that can simulate some of the symptoms experienced by people with dementia. It has attracted visitors from 149 countries and has been shared over 5,000 times on social media.




4,644

The number of times we were **featured in the media** – an impressive 59% increase in coverage from the previous year. We provide expert reaction to worldwide dementia research developments to help make sure the public knows what progress is being made.

107

How many published academic papers our funding helped support last year, each of which contributed to the worldwide knowledge base on dementia. At 107 studies, our contribution is almost three times greater than the second placed UK dementia charity at 37.



£23,683,381

How much we currently invest in 127 ongoing research projects.

Our finances




400+

The number of campaigners who have joined our network to call for more research into dementia.



2,800

People who've signed up to donate their brain for research as part of our Brains for Dementia Research programme



Category	Amount
Voluntary	13,508,238
Investment	578,886
Activities for generating funds	145,428
Total	14,232,552



Our charitable activity this year, including £7.6 million in 62 new research projects.



With our new research commitments this year, this is the amount we've now awarded to 542 research projects since 1992.



Charitable activities	9,736,251
Costs of generating funds	3,665,898
Governance	117,464
Total	13,519,613



Thank you

Ian Wilson, Director of Fundraising at Alzheimer's Research UK, says we can only maintain our great progress with your support.



On a rainy Sunday morning in July 2014, I met some of the 500 people who came to walk five to 10km with their families to raise money for dementia research at our most successful **Big Walk** to date.



It was inspiring to hear the many reasons why people choose to support us, from personal stories to an absolute belief in the need to find a cure for this dreadful condition. Whatever people's motivation, we need many more supporters to join us to help us achieve the ambitions that we have set.

If you want to find out more about the many ways you can support us, visit www.alzheimersresearchuk.org.

Thank you to everyone who has helped us achieve such incredible things this year. We receive no funding from government towards our research, so we rely on the generosity of the general public to support our work.

David Mayhew CBE
Chairman, Alzheimer's Research UK



The following people and organisations have made a significant contribution to our research in the last year:

The Adint Charitable Trust	CHK Charities Ltd	The Jordan Charitable Foundation	The R S Macdonald Charitable Trust
The Alborada Trust	Constance Travis Charitable Trust	The Magnet Charitable Trust	The Saintbury Trust
Alzheimer's Foundation	The Eric and Margaret Kinder Charitable Trust	The Peacock Charitable Trust	The Swire Charitable Trust
Henry Angest	The Eveson Charitable Trust	Peter Dixon Charitable Trust	The Violet and Milo Cripps Charitable Trust
Awareness Fund	Houghton Dunn Charitable Trust	Philip King Charitable Trust	Bradley Wickens
The BACIT Foundation	J Macdonald Menzies Charitable Trust	Pilkington Charities Fund	The Zochonis Charitable Trust
David Barnett	John Laing Charitable Trust	Robert Luff Foundation Ltd	
The Cadogan Charity			
The Charity Maples Trust			

We would also like to thank the many supporters who have chosen to remain anonymous.

Thank you to the following companies with which we have had key partnerships in 2014 and to all of the staff who have contributed to the success of the partnerships:

Anglia Regional Cooperative	Coutts & Co	Iceland Foods Ltd	PageGroup
BNY Mellon	ICAP	Insight Investment	The Perfume Shop

We would like to thank everyone who has remembered us through a Gift in their Will this year. We are extremely grateful.

**Alzheimer's
Research UK**
Defeating Dementia

Alzheimer's Research UK
3 Riverside
Granta Park
Cambridge
CB21 6AD

Telephone **0300 111 5555**
Email **enquiries@alzheimersresearchuk.org**
Website **www.alzheimersresearchuk.org**